vs

Side-by-side financial comparison of Blue Hat Interactive Entertainment Technology (BHAT) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $13.1M, roughly 1.5× Blue Hat Interactive Entertainment Technology). Blue Hat Interactive Entertainment Technology runs the higher net margin — -9.9% vs -177.4%, a 167.5% gap on every dollar of revenue.

Blue Hat Interactive Entertainment Technology develops and produces interactive entertainment products including AR games, smart interactive toys, and immersive leisure content. It primarily serves mainland China's consumer market, with expanding distribution across Southeast Asia, focusing on family and youth entertainment segments.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

BHAT vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.5× larger
LAB
$19.6M
$13.1M
BHAT
Higher net margin
BHAT
BHAT
167.5% more per $
BHAT
-9.9%
-177.4%
LAB

Income Statement — Q2 FY2025 vs Q3 FY2025

Metric
BHAT
BHAT
LAB
LAB
Revenue
$13.1M
$19.6M
Net Profit
$-1.3M
$-34.7M
Gross Margin
8.3%
48.5%
Operating Margin
-9.4%
-168.5%
Net Margin
-9.9%
-177.4%
Revenue YoY
-11.5%
Net Profit YoY
-28.8%
EPS (diluted)
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BHAT
BHAT
LAB
LAB
Q3 25
$19.6M
Q2 25
$13.1M
$21.8M
Q1 25
$40.8M
Q3 24
$22.1M
Q2 24
$46.3M
$22.5M
Q1 24
$45.5M
Q4 23
$28.2M
Q3 23
$25.4M
Net Profit
BHAT
BHAT
LAB
LAB
Q3 25
$-34.7M
Q2 25
$-1.3M
$-33.5M
Q1 25
$-26.0M
Q3 24
$-26.9M
Q2 24
$-4.4M
$-45.7M
Q1 24
$-32.2M
Q4 23
$-19.8M
Q3 23
$-21.0M
Gross Margin
BHAT
BHAT
LAB
LAB
Q3 25
48.5%
Q2 25
8.3%
48.8%
Q1 25
48.4%
Q3 24
54.9%
Q2 24
0.2%
46.1%
Q1 24
53.1%
Q4 23
47.6%
Q3 23
44.0%
Operating Margin
BHAT
BHAT
LAB
LAB
Q3 25
-168.5%
Q2 25
-9.4%
-118.1%
Q1 25
-80.8%
Q3 24
-120.9%
Q2 24
-8.8%
-134.5%
Q1 24
-132.2%
Q4 23
-75.9%
Q3 23
-83.5%
Net Margin
BHAT
BHAT
LAB
LAB
Q3 25
-177.4%
Q2 25
-9.9%
-153.7%
Q1 25
-63.8%
Q3 24
-122.0%
Q2 24
-9.4%
-203.3%
Q1 24
-70.6%
Q4 23
-70.2%
Q3 23
-82.8%
EPS (diluted)
BHAT
BHAT
LAB
LAB
Q3 25
$-0.09
Q2 25
$-0.09
Q1 25
$-0.07
Q3 24
$-0.07
Q2 24
$-0.12
Q1 24
$-0.27
Q4 23
$-0.24
Q3 23
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BHAT
BHAT
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$14.3K
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$32.1M
$399.7M
Total Assets
$75.2M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BHAT
BHAT
LAB
LAB
Q3 25
$129.4M
Q2 25
$14.3K
$158.6M
Q1 25
$150.9M
Q3 24
$210.6M
Q2 24
$407.6K
$269.8M
Q1 24
$287.1M
Q4 23
$51.7M
Q3 23
$79.7M
Total Debt
BHAT
BHAT
LAB
LAB
Q3 25
Q2 25
Q1 25
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Q4 23
$63.5M
Q3 23
$64.6M
Stockholders' Equity
BHAT
BHAT
LAB
LAB
Q3 25
$399.7M
Q2 25
$32.1M
$424.5M
Q1 25
$454.6M
Q3 24
$489.3M
Q2 24
$40.6M
$510.3M
Q1 24
$577.3M
Q4 23
$-148.1M
Q3 23
$-131.7M
Total Assets
BHAT
BHAT
LAB
LAB
Q3 25
$539.6M
Q2 25
$75.2M
$557.0M
Q1 25
$579.6M
Q3 24
$681.5M
Q2 24
$49.3M
$708.7M
Q1 24
$777.7M
Q4 23
$323.1M
Q3 23
$339.3M
Debt / Equity
BHAT
BHAT
LAB
LAB
Q3 25
Q2 25
Q1 25
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×
Q4 23
Q3 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BHAT
BHAT
LAB
LAB
Operating Cash FlowLast quarter
$2.6M
$-22.2M
Free Cash FlowOCF − Capex
$-23.1M
FCF MarginFCF / Revenue
-118.1%
Capex IntensityCapex / Revenue
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BHAT
BHAT
LAB
LAB
Q3 25
$-22.2M
Q2 25
$2.6M
$-20.7M
Q1 25
$-30.3M
Q3 24
$-27.9M
Q2 24
$-39.0M
Q1 24
$-62.5M
Q4 23
$-14.1M
Q3 23
$-11.4M
Free Cash Flow
BHAT
BHAT
LAB
LAB
Q3 25
$-23.1M
Q2 25
$-22.6M
Q1 25
$-35.3M
Q3 24
$-30.1M
Q2 24
$-41.0M
Q1 24
$-63.3M
Q4 23
$-14.1M
Q3 23
$-12.3M
FCF Margin
BHAT
BHAT
LAB
LAB
Q3 25
-118.1%
Q2 25
-103.6%
Q1 25
-86.6%
Q3 24
-136.4%
Q2 24
-182.2%
Q1 24
-138.9%
Q4 23
-50.2%
Q3 23
-48.6%
Capex Intensity
BHAT
BHAT
LAB
LAB
Q3 25
4.5%
Q2 25
8.7%
Q1 25
12.4%
Q3 24
10.2%
Q2 24
8.6%
Q1 24
1.7%
Q4 23
0.3%
Q3 23
3.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BHAT
BHAT

Segment breakdown not available.

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons